Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.57 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.57 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958220 | 0.88 | KIF11 (0.63) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3966803 | 0.88 | KIF11 (0.68) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3957584 | 0.88 | KIF11 (0.57) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5246236 | 0.87 | KIF11 (0.52) | KIF11KIF23 | |
| SCHEMBL6209979 | 0.86 | KIF11 (0.54) | KIF11KIF23MAP1LC3BKCNH2 | |
| SCHEMBL6207373 | 0.84 | KIF11 (0.53) | KIF11KIF23MAP1LC3B | |
| SCHEMBL3959159 | 0.83 | KIF11 (0.60) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL6209231 | 0.83 | KIF11 (0.53) | KIF11KIF23 | |
| SCHEMBL3959566 | 0.82 | KIF11 (0.59) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3863752 | 0.82 | KIF11 (0.81) | KIF11KIF23 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009037512-A1 | THERAPEUTIC METHODS 013 | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | claimed |
| WO-2008122798-A2 | PHARMACEUTICAL COMPOSITION OF AN EG5 INHIBITOR AND A MICROTUBULE INTERFERING AGENT FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | claimed |
| WO-2009037512-A1 | THERAPEUTIC METHODS 013 | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008122798-A2 | PHARMACEUTICAL COMPOSITION OF AN EG5 INHIBITOR AND A MICROTUBULE INTERFERING AGENT FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
| EP-1781674-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |